Maertens et al. S rial No. 09/899,303

number 2), into the amino acid sequences of the respective E1 or E2 proteins as shown in the sequence listing.

Page 38, amend the paragraph spanning lines 32-35 as follows:

bv

Figures 35A-1 to 35A-8: Antibody levels to the different HCV

antigens (Core 1, Core 2, E2HCVR, NS3) for NR and LTR followed during treatment and over a period of 6 to 12 months after treatment determined by means of the LIAscan method. The

average values are indicated by the curves with the open squares.

Page 39, delete the paragraph spanning lines 1-4, and insert the following

therefor:

- 13130

-- Figures 35B-1 to 35B-8: Antibody levels to the different HCV

antigens (NS4, NS5, E1 and E2) for NR and LTR followed during
treatment and over a period of 6 to 12 months after treatment
determined by means of the LIAscan method. The average values
are indicated by the curve with the open squares.--

Page 39, amend the paragraph spanning lines 6-7 as follows:

Figures 36A and 36B: Average E1 antibody (E1Ab) and E2 antibody (E2Ab) levels in the LTR and NR groups.

Page 39, amend the paragraph spanning lines 8 and 9 as follows:

Figures 36A-D: Averages E1 antibody (E1Ab) levels for non-responders (NR) and long term responders (LTR) for type 1b and type 3a.